Heska’s Corporation has recently signed a new employment agreement with the CEO, Kevin Wilson, who is expanding his tenure for at least another four years.The veterinarian pharmacological and diagnostic company signed an employment agreement once again with Wilson on June 8, 2021, as reported by the documents filed with the United States Securities and Exchange Commission.
The agreement got outdated and is now replaced with an existing contract set to expire on December 31, 2020.The new agreement contains a few amendments to the previous deal, automatic one-year renewals, with a notice of six months regarding the non-renewal by either of the parties.
Wilson is expected to make a base salary of $1 million, along with a bonus targeted at the least amount of $500,000. It also provides for a scholarship of 34,800 performance-vesting stock decisions and also a grant of 180,000 shares of performance-vesting restricted stock at the maximum performance.
One-half of the 34,800 performance-vesting stock options will be entrusted when the average closing price of Heska’s stock over 20 days will be equal to $300, with the remainder devolving when the stock price becomes equal to $350.The 180,000 shares would be earned only if specific performance targets and goals are reached, along with performance-based bonuses and incentives. Heska’s stock closed at $206.05 on Thursday, which is $3.08 up than before. There is an increase of around 1.52% in the closing stock rates.